LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

Strona główna・Stock List・CytoSorbents Corp

CytoSorbents Corp

Open

SectorHealthcare

0.46 -2.13

Buy Sell

Overview

Share price change

24h

Current

Min

0.46

Max

0.49

Key metrics
By Trading Economics
Income	368K -5.1M
Sales	-370K 8.9M
EPS	-0.08
Profit margin	-57.863
Employees	129
EBITDA	648K -3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+53.06% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-11M 29M
Previous open	2.59
Previous close	0.46

News Sentiment

By Acuity

46%

54%

142 / 344 Ranking in Healthcare

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 maj 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 maj 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 maj 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 maj 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 maj 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 maj 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 maj 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 maj 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 maj 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 maj 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 maj 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 maj 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 maj 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 maj 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 maj 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 maj 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 maj 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 maj 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

53.06% upside

12 Months Forecast

Average 0.75 USD 53.06%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Sentiment

By Acuity

142 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.